Tiger Brokers

Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says

MT Newswires Live
Sep 28

Pfizer's (PFE) new phase 3 studies of tilrekimig in atopic dermatitis and asthma may drive upside if results are positive, UBS Securities said Friday in a report.

The adult atopic-dermatitis study will be run head-to-head against Dupixent, which is developed jointly by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN), and UBS said the potential commercial contribution is not yet reflected in consensus estimates.

Topline data released in March showed competitive placebo-adjusted EASI-75 rates of about 50% at the middle and high doses, and UBS said Pfizer is likely working to maximize efficacy at the middle-dose level.

UBS maintained its neutral rating on Pfizer stock with a $27 price target.

Price: 28.59, Change: -0.09, Percent Change: -0.30

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10